Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population‐based study

The authors hypothesized that epigenetic changes may help to clarify the underlying biologic mechanism linking aspirin use to breast cancer prognosis. To the authors' knowledge, this is the first epidemiologic study to examine whether global methylation and/or tumor promoter methylation of breast cancer‐related genes interact with aspirin use to impact mortality after breast cancer.

[1]  Yao Lin,et al.  Evaluation of the prognostic and physiological functions of death associated protein kinase 1 in breast cancer , 2018, Oncology letters.

[2]  A. Neugut,et al.  Pre-diagnostic aspirin use and mortality after breast cancer , 2018, Cancer Causes & Control.

[3]  Robert Huether,et al.  Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer , 2017, JAMA oncology.

[4]  S. Abbasi,et al.  The Effects of Sex Protein Receptors and Sex Steroid Hormone Gene Polymorphisms on Breast Cancer Risk. , 2017, Journal of the National Medical Association.

[5]  Yusuke Nakamura,et al.  Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention , 2017, Cancer Prevention Research.

[6]  D. Edwards,et al.  Progesterone Receptor Signaling Mechanisms. , 2016, Journal of molecular biology.

[7]  Yan Shi,et al.  Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival , 2016, Oncotarget.

[8]  P. Elwood,et al.  Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies , 2016, PloS one.

[9]  A. Neugut,et al.  DNA methylation modifies the association between obesity and survival after breast cancer diagnosis , 2016, Breast Cancer Research and Treatment.

[10]  A. Neugut,et al.  Sources of polycyclic aromatic hydrocarbons are associated with gene-specific promoter methylation in women with breast cancer. , 2016, Environmental research.

[11]  S. Zhong,et al.  Aspirin Use and Risk of Breast Cancer: Systematic Review and Meta-analysis of Observational Studies , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[12]  A. Neugut,et al.  Global DNA Methylation, Measured by the Luminometric Methylation Assay (LUMA), Associates with Postmenopausal Breast Cancer in Non-Obese and Physically Active Women , 2015, Journal of Cancer.

[13]  S. Zhong,et al.  Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies , 2015, Breast Cancer Research and Treatment.

[14]  K. Bennett,et al.  Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study. , 2014, Cancer research.

[15]  E. Yiannakopoulou.  Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents - implications for cancer treatment and chemoprevention , 2014, Cellular Oncology.

[16]  M. Röösli,et al.  Modulation of Age- and Cancer-Associated DNA Methylation Change in the Healthy Colon by Aspirin and Lifestyle , 2014, Journal of the National Cancer Institute.

[17]  C. McCowan,et al.  Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study , 2014, British Journal of Cancer.

[18]  K. Nathanson,et al.  Common breast cancer risk variants in the post-COGS era: a comprehensive review , 2013, Breast Cancer Research.

[19]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[20]  B. Moore,et al.  COX-2 Expression Is Upregulated by DNA Hypomethylation after Hematopoietic Stem Cell Transplantation , 2012, The Journal of Immunology.

[21]  M. Laiho,et al.  Maintenance of genomic integrity after DNA double strand breaks in the human prostate and seminal vesicle epithelium: The best and the worst , 2012, Molecular oncology.

[22]  A. Neugut,et al.  The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project , 2012, Cancer Causes & Control.

[23]  A. Rogers,et al.  Molecular Pathways: The Role of NR4A Orphan Nuclear Receptors in Cancer , 2012, Clinical Cancer Research.

[24]  H. Putter,et al.  Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study , 2012, Breast Cancer Research and Treatment.

[25]  A. Neugut,et al.  DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population‐based study , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  M. Fraga,et al.  Epigenetics and the environment: emerging patterns and implications , 2012, Nature Reviews Genetics.

[27]  S. Edge,et al.  Use of Nonsteroidal Anti-inflammatory Drugs and Survival Following Breast Cancer Diagnosis , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[28]  G. Colditz,et al.  COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin , 2011, Breast Cancer Research and Treatment.

[29]  Andrea Baccarelli,et al.  Epigenetics and lifestyle. , 2011, Epigenomics.

[30]  J. Cerhan,et al.  Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study , 2011, Breast Cancer Research and Treatment.

[31]  C. Huttenhower,et al.  Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors , 2010, Molecular Cancer.

[32]  G. Watanabe,et al.  Long Interspersed Nuclear Element 1 Hypomethylation Is a Marker of Poor Prognosis in Stage IA Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[33]  A. Neugut,et al.  BRCA1 promoter methylation is associated with increased mortality among women with breast cancer , 2009, Breast Cancer Research and Treatment.

[34]  S. Cole,et al.  Overadjustment Bias and Unnecessary Adjustment in Epidemiologic Studies , 2009, Epidemiology.

[35]  J. Ghosn,et al.  Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer , 2005, BMC Cancer.

[36]  Christian B. Woods,et al.  Analysis of repetitive element DNA methylation by MethyLight , 2005, Nucleic acids research.

[37]  S. Lippman,et al.  Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. DuBois,et al.  Aspirin and breast cancer prevention: the estrogen connection. , 2004, JAMA.

[39]  A. Neugut,et al.  Rates of caesarean section and instrumental vaginal delivery in nulliparous women after low concentration epidural infusions or opioid analgesia: systematic review , 2004, British medical journal.

[40]  D. Collet.  Modelling Survival Data in Medical Research , 2004 .

[41]  J. Issa,et al.  A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. , 2004, Nucleic acids research.

[42]  J. Satagopan,et al.  A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.

[43]  G. Anderson,et al.  Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. , 2003, Cancer research.

[44]  A. Folsom,et al.  Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[45]  Charles Maynard,et al.  A primer and comparative review of major US mortality databases. , 2002, Annals of epidemiology.

[46]  Martin Widschwendter,et al.  DNA methylation and breast carcinogenesis , 2002, Oncogene.

[47]  Mary Beth Terry,et al.  The Long Island Breast Cancer Study Project: Description of a Multi-Institutional Collaboration to Identify Environmental Risk Factors for Breast Cancer , 2002, Breast Cancer Research and Treatment.

[48]  U. Lehmann,et al.  Quantitative assessment of promoter hypermethylation during breast cancer development. , 2002, The American journal of pathology.

[49]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[50]  J. R. Morris,et al.  Genes, genetics, and epigenetics: a correspondence. , 2001, Science.

[51]  N. Davidson,et al.  DNA methylation in breast cancer. , 2001, Endocrine-related cancer.

[52]  L. Bégin,et al.  Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  P. Laird,et al.  Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. , 2000, Cancer research.

[54]  P. Laird,et al.  CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. , 1999, Cancer research.

[55]  Paul D. Allison,et al.  Survival analysis using sas®: a practical guide , 1995 .

[56]  W C Willett,et al.  The causes and prevention of cancer. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[57]  G Block,et al.  A data-based approach to diet questionnaire design and testing. , 1986, American journal of epidemiology.

[58]  M. Ip,et al.  Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. , 1983, Cancer research.

[59]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[60]  Mounir Frikha,et al.  CpG methylation of APC promoter 1A in sporadic and familial breast cancer patients. , 2017, Cancer biomarkers : section A of Disease markers.

[61]  A. Jemal,et al.  Breast cancer statistics, 2015: Convergence of incidence rates between black and white women , 2016, CA: a cancer journal for clinicians.

[62]  A. Neugut,et al.  Gene-Specific Promoter Methylation Status in Hormone-Receptor-Positive Breast Cancer Associates with Postmenopausal Body Size and Recreational Physical Activity. , 2015, International journal of cancer and clinical research.

[63]  A. Neugut,et al.  Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients , 2011, Breast Cancer Research and Treatment.

[64]  A. Neugut,et al.  Gene promoter methylation is associated with increased mortality among women with breast cancer , 2009, Breast Cancer Research and Treatment.

[65]  A. Jemal,et al.  Breast Cancer Statistics , 2013 .

[66]  Stanley Lemeshow,et al.  Applied Logistic Regression, Second Edition , 1989 .

[67]  M. Cravo,et al.  Global DNA hypomethylation in breast carcinoma , 1999, Cancer.

[68]  G. Shaw,et al.  Maternal pesticide exposure from multiple sources and selected congenital anomalies. , 1999 .

[69]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.